LONDON (AFX) - SR Pharma PLC said the US Food and Drug Administration has
approved an Investigational New Drug application for a second small interfering RNA (siRNA) therapeutic product based on its proprietary chemistry.
Approval has been given to a treatment for acute kidney injury, AKIi-5, which is being developed by Quark Biotech. The product was licensed to Quark Biotech by SR Pharma subsidiary Atugen and its structure and composition matter is protected by Atugen's patent portfolio.
SR Pharma chief executive Iain Ross said: 'We are very excited by this
achievement, as this is the second product based upon our proprietary AtuRNAi
chemistry which has been approved for use in humans.
Last month the company announced that the AtuRNAi compound RTP-801i, which it sub-licensed to Pfizer through Quark Biotech for the treatment of Age-related Macular Degeneration, was moving into the clinic.
COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.